August 19, 2024 02:50 PM EDTUpdated August 20, 11:15 AM
Pharma

Half of IRA ne­go­ti­a­tion sav­ings to come from three drugs, Brook­ings finds

Zachary Brennan

Senior Editor

For the first 10 drug prices ne­go­ti­at­ed un­der the In­fla­tion Re­duc­tion Act, about one-half of the es­ti­mat­ed $6 bil­lion in Medicare sav­ings is the re­sult …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times